Eric Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric Wang has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Iannis Aifantis
Department of Pathology, NYU Grossman School of Medicine, New York, USA
30 shared publications - Aristotelis Tsirigos
Department of Pathology, New York University Grossman School of Medicine, New York, USA
29 shared publications - Jochen Imig
Max-Planck-Institute for Molecular Physiology , Otto-Hahn-Str. 11, 44227 Dortmund
21 shared publications - Iman Osman
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
20 shared publications - Palaniraja Thandapani
Department of Pathology and Laura & Isaac Perlmutter Cancer Center, NYU School of Medicine, New York, USA
20 shared publications - Pietro Berico
Department of Pathology and Laura & Isaac Perlmutter Cancer Center, NYU School of Medicine, New York, New York
20 shared publications
Latest Publications
- 25 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (838) , eady2936
Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia
Inactivation of tumor suppressor genes (TSGs) imparts a cellular fitness in cancers, including in acute myeloid leukemia (AML). The detection of silenced TSGs without direct mutations presents challenges in designing targeted cancer treatments, yet it also opens a therapeutic opportunity to restore their function. In this study, we identified the transcriptional repressor ZBTB7A as a TSG that is down-regulated in samples from patients with AML and is associated with poor survival outcomes. Loss of ZBTB7A amplifies TNF signaling, driving a dysfunctional inflammatory state that accelerates AML progression in vivo. Mechanistically, the mRNA decay factor ZFP36L2 binds to the 3′ untranslated region (3′UTR) of ZBTB7A , promoting its transcript degradation in human AML cells. To identify therapeutic targets, we developed a CRISPR-based screening approach coupled with fluorescence in situ hybridization and flow cytometry (FISH-Flow), pinpointing the KDM4 family of histone demethylases as a vulnerability to restore ZBTB7A function. Pharmacologic inhibition of KDM4 up-regulated ZBTB7A expression, promoted terminal differentiation in patient-derived xenograft models, and demonstrated broad antileukemic efficacy across AML subtypes as well as preserved normal hematopoiesis. These findings reveal regulatory mechanisms of ZBTB7A and support epigenetic therapy as a promising strategy to reactivate its tumor suppressor function in hematologic cancers.
- 25 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (838) , eady2936
Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia
Inactivation of tumor suppressor genes (TSGs) imparts a cellular fitness in cancers, including in acute myeloid leukemia (AML). The detection of silenced TSGs without direct mutations presents challenges in designing targeted cancer treatments, yet it also opens a therapeutic opportunity to restore their function. In this study, we identified the transcriptional repressor ZBTB7A as a TSG that is down-regulated in samples from patients with AML and is associated with poor survival outcomes. Loss of ZBTB7A amplifies TNF signaling, driving a dysfunctional inflammatory state that accelerates AML progression in vivo. Mechanistically, the mRNA decay factor ZFP36L2 binds to the 3′ untranslated region (3′UTR) of ZBTB7A , promoting its transcript degradation in human AML cells. To identify therapeutic targets, we developed a CRISPR-based screening approach coupled with fluorescence in situ hybridization and flow cytometry (FISH-Flow), pinpointing the KDM4 family of histone demethylases as a vulnerability to restore ZBTB7A function. Pharmacologic inhibition of KDM4 up-regulated ZBTB7A expression, promoted terminal differentiation in patient-derived xenograft models, and demonstrated broad antileukemic efficacy across AML subtypes as well as preserved normal hematopoiesis. These findings reveal regulatory mechanisms of ZBTB7A and support epigenetic therapy as a promising strategy to reactivate its tumor suppressor function in hematologic cancers.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in RNA Biology
- Vol. 22 (1) , 1-23
RNA binding of GAPDH controls transcript stability and protein translation in acute myeloid leukemia
Dysregulation of RNA binding proteins (RBPs) is a hallmark in cancerous cells. In acute myeloid leukaemia (AML) RBPs are key regulators of tumour proliferation. While classical RBPs have defined RNA binding domains, RNA recognition and function in AML by non-canonical RBPs (ncRBPs) remain unclear. Given the inherent complexity of targeting AML broadly, our goal was to uncover potential ncRBP candidates critical for AML survival using a CRISPR/Cas-based screening. We identified the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a pro-proliferative factor in AML cells. Based on cross-linking and immunoprecipitation (CLIP), we are defining the global targetome, detecting novel RNA targets mainly located within 5'UTRs, including GAPDH, RPL13a, and PKM. The knockdown of GAPDH unveiled genetic pathways related to ribosome biogenesis, translation initiation, and regulation. Moreover, we demonstrated a stabilizing effect through GAPDH binding to target transcripts including its own mRNA. The present findings provide new insights on the RNA functions and characteristics of GAPDH in AML.
- 1 November 2025
- Published by Taylor & Francis in RNA Biology
- Vol. 22 (1) , 1-23
Open AccessRNA binding of GAPDH controls transcript stability and protein translation in acute myeloid leukemia
Dysregulation of RNA binding proteins (RBPs) is a hallmark in cancerous cells. In acute myeloid leukaemia (AML) RBPs are key regulators of tumour proliferation. While classical RBPs have defined RNA binding domains, RNA recognition and function in AML by non-canonical RBPs (ncRBPs) remain unclear. Given the inherent complexity of targeting AML broadly, our goal was to uncover potential ncRBP candidates critical for AML survival using a CRISPR/Cas-based screening. We identified the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a pro-proliferative factor in AML cells. Based on cross-linking and immunoprecipitation (CLIP), we are defining the global targetome, detecting novel RNA targets mainly located within 5'UTRs, including GAPDH, RPL13a, and PKM. The knockdown of GAPDH unveiled genetic pathways related to ribosome biogenesis, translation initiation, and regulation. Moreover, we demonstrated a stabilizing effect through GAPDH binding to target transcripts including its own mRNA. The present findings provide new insights on the RNA functions and characteristics of GAPDH in AML.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (5) , 464-483
An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance
Aberrant levels or structures of RNA isoforms are a hallmark of many cancers, including acute myeloid leukemia (AML), yet their role in AML chemoresistance remains unclear. We conducted a paired analysis of RNA isoform changes in patients with AML before therapy and at relapse after chemotherapy and identified intragenic DNA methylation at the proximal promoter of the transcription factor RUNX1, which resulted in elevated expression of the long-isoform RUNX1C through its alternative distal promoter. The unique N-terminal region of RUNX1C orchestrated an isoform-specific transcriptional program that promoted chemoresistance, with its direct target BTG2 playing a role in chemotherapy resistance. BTG2 promoted rRNA deadenylation, resulting in decreased mRNA expression and stability. Deletion of rRNAs increased cellular quiescence. Moreover, RNA-based targeting of RUNX1C reactivated quiescent leukemia cells and enhanced chemotherapy efficacy. These findings delineated an isoform-specific transcriptional circuit that governed chemotherapy response, providing a potential therapeutic strategy to mitigate AML recurrence. Significance: This study identifies RUNX1C as a contributor to AML chemoresistance and an inducer of quiescence through BTG2. Targeting RUNX1C with RNA-based approaches disrupts this state and improves chemotherapy response, highlighting RUNX1C inhibition as a promising strategy to overcome resistance and enhance treatment efficacy in AML.
- 9 July 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (5) , 464-483
Open AccessAn Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance
Aberrant levels or structures of RNA isoforms are a hallmark of many cancers, including acute myeloid leukemia (AML), yet their role in AML chemoresistance remains unclear. We conducted a paired analysis of RNA isoform changes in patients with AML before therapy and at relapse after chemotherapy and identified intragenic DNA methylation at the proximal promoter of the transcription factor RUNX1, which resulted in elevated expression of the long-isoform RUNX1C through its alternative distal promoter. The unique N-terminal region of RUNX1C orchestrated an isoform-specific transcriptional program that promoted chemoresistance, with its direct target BTG2 playing a role in chemotherapy resistance. BTG2 promoted rRNA deadenylation, resulting in decreased mRNA expression and stability. Deletion of rRNAs increased cellular quiescence. Moreover, RNA-based targeting of RUNX1C reactivated quiescent leukemia cells and enhanced chemotherapy efficacy. These findings delineated an isoform-specific transcriptional circuit that governed chemotherapy response, providing a potential therapeutic strategy to mitigate AML recurrence. Significance: This study identifies RUNX1C as a contributor to AML chemoresistance and an inducer of quiescence through BTG2. Targeting RUNX1C with RNA-based approaches disrupts this state and improves chemotherapy response, highlighting RUNX1C inhibition as a promising strategy to overcome resistance and enhance treatment efficacy in AML.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Melanoma being one of the most common and deadliest skin cancers has been increasing since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays, the standard of care of advanced melanoma is resection, followed by immune checkpoint inhibition–based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistance. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long noncoding RNAs (lncRNA) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistance; however, systematic screens to uncover novel functional lncRNAs are scarce. In this study, we profile differentially expressed lncRNAs in patient-derived short-term metastatic cultures and BRAF–MEK inhibition–resistant cells. We conduct a focused growth-related CRISPR inhibition screen of overexpressed lncRNAs, validate, and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities, and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance in melanoma.Significance:LncRNAs have emerged as novel players in regulating many cellular aspects also in melanoma. The number of functional significances of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR inhibition growths screens. Our results broaden the characterized lncRNAs as potential targets for future therapeutic applications.
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Melanoma being one of the most common and deadliest skin cancers has been increasing since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays, the standard of care of advanced melanoma is resection, followed by immune checkpoint inhibition–based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistance. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long noncoding RNAs (lncRNA) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistance; however, systematic screens to uncover novel functional lncRNAs are scarce. In this study, we profile differentially expressed lncRNAs in patient-derived short-term metastatic cultures and BRAF–MEK inhibition–resistant cells. We conduct a focused growth-related CRISPR inhibition screen of overexpressed lncRNAs, validate, and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities, and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance in melanoma.Significance:LncRNAs have emerged as novel players in regulating many cellular aspects also in melanoma. The number of functional significances of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR inhibition growths screens. Our results broaden the characterized lncRNAs as potential targets for future therapeutic applications.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA XLOC_030781 expression data analysis in cancer and clinical melanoma samples. A, Pan-cancer expression analysis using TCGA. SKCM, skin cutaneous melanoma. B, UCSC genome browser snap shots of H3K27ac ChIP-seq data from melanoma (MM, black), non-malignant skin biopsies (NHM, black), foreskin sample (green), and other malignant samples (other colors) at the XLOC_030781/ENSG00000287723 locus. Pink bar shows the peak area of interest in the vicinity of XLOC_030781 promoter. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney Chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA XLOC_030781 expression data analysis in cancer and clinical melanoma samples. A, Pan-cancer expression analysis using TCGA. SKCM, skin cutaneous melanoma. B, UCSC genome browser snap shots of H3K27ac ChIP-seq data from melanoma (MM, black), non-malignant skin biopsies (NHM, black), foreskin sample (green), and other malignant samples (other colors) at the XLOC_030781/ENSG00000287723 locus. Pink bar shows the peak area of interest in the vicinity of XLOC_030781 promoter. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney Chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA metaanalysis of lncRNA XLOC_030781
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
TCGA metaanalysis of lncRNA XLOC_030781
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
LncRNA candidate selection for CRISPRi screen and expression of lncRNAs associated to melanomagenesis. A, Flow diagram of integrated RNA- and ChIP-seq for the preselection of lncRNAs. Selection parameters are FDR < 5%, log fc > 0.75, and CPM > 1 in higher expressed cell type, either histone mark (H3K4me3 or H3K27ac) in the higher expressed cell type; no mono-exonic lncRNAs and log fc ≥ 0.5 between investigated cell type and either WM1361a or 501mel. B, Heatmap of differentially expressed lncRNAs by RNA-seq in patient/donor-derived melanocytes (n = 4) and metastatic STCs (BM, brain metastasis, n = 5; LN, lymph node metastasis, n = 4) and melanoma cell lines 501mel (n = 4) and WM1361a (n = 3). C, Heatmap showing differential lncRNA expression in the SK-Mel239 parental melanoma cell line versus BRAF and 1059 MEKi-resistant cell line (n = 2). D, Boxplot showing the log2 CPM expression of selected melanoma-associated lncRNAs SAMMSON, MEG3, H19, and PCAT1 in melanocytes (n = 4), brain metastasis (n = 5), and LN STCs (n = 4) detected by RNA-seq. DE, differentially expressed; Mets, metastasis; TSS, transcription start site.
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
LncRNA candidate selection for CRISPRi screen and expression of lncRNAs associated to melanomagenesis. A, Flow diagram of integrated RNA- and ChIP-seq for the preselection of lncRNAs. Selection parameters are FDR < 5%, log fc > 0.75, and CPM > 1 in higher expressed cell type, either histone mark (H3K4me3 or H3K27ac) in the higher expressed cell type; no mono-exonic lncRNAs and log fc ≥ 0.5 between investigated cell type and either WM1361a or 501mel. B, Heatmap of differentially expressed lncRNAs by RNA-seq in patient/donor-derived melanocytes (n = 4) and metastatic STCs (BM, brain metastasis, n = 5; LN, lymph node metastasis, n = 4) and melanoma cell lines 501mel (n = 4) and WM1361a (n = 3). C, Heatmap showing differential lncRNA expression in the SK-Mel239 parental melanoma cell line versus BRAF and 1059 MEKi-resistant cell line (n = 2). D, Boxplot showing the log2 CPM expression of selected melanoma-associated lncRNAs SAMMSON, MEG3, H19, and PCAT1 in melanocytes (n = 4), brain metastasis (n = 5), and LN STCs (n = 4) detected by RNA-seq. DE, differentially expressed; Mets, metastasis; TSS, transcription start site.
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Table S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Table S1 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
CRISPRi screen lncRNA hit functional characterization. A, Flow cytometry–based dotmplot showing GFP and mCherry signal as proxy for sgRNA and dCas9 expression (left). 7-AAD fluorescence–dependent cell cycle analysis in 501mel-dCas9-KRAB (top) and WM136a-dCas9-KRAB (bottom) cell lines upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 CRISPRi knockdown (rigth). Note that the top panel is plotted linear and bottom logarithmic because of better cell cycle–gating parameters. B, Cell cycle phase quantification based on A in percent of cells (n = 2). C, PARP cleavage apoptosis assay performed by Western blotting upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 knockdown in 501meld-Cas9-KRAB and WM1361a-dCas9-KRAB Representative Western blots (top). GAPDH detection was used as a loading control; densitometric quantification of apoptosis as cleaved PARP/GAPDH protein ratio (bottom; average of n = 2). sgROSA served as negative control and etoposide apoptosis inducer as positive control. D, Re-analysis of 7-AAD cell cycle assay staining using exact same gating parameters for sub-G1 cellular fraction indicative of apoptosis. E, Transwell cell migration assay. Fluorescence photomicrographs show calcein-stained migrated cells of sgBDNF-AS, sgGMDS-AS1, and sgXLOC_030781 knocked-down 501mel-dCas9-KRAB cells vs. sgROSA negative control and quantification of average sum count cell numbers (n = 2).
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
CRISPRi screen lncRNA hit functional characterization. A, Flow cytometry–based dotmplot showing GFP and mCherry signal as proxy for sgRNA and dCas9 expression (left). 7-AAD fluorescence–dependent cell cycle analysis in 501mel-dCas9-KRAB (top) and WM136a-dCas9-KRAB (bottom) cell lines upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 CRISPRi knockdown (rigth). Note that the top panel is plotted linear and bottom logarithmic because of better cell cycle–gating parameters. B, Cell cycle phase quantification based on A in percent of cells (n = 2). C, PARP cleavage apoptosis assay performed by Western blotting upon sgBDNF-AS, sgXLOC_030781, and sgGMDS-AS1 knockdown in 501meld-Cas9-KRAB and WM1361a-dCas9-KRAB Representative Western blots (top). GAPDH detection was used as a loading control; densitometric quantification of apoptosis as cleaved PARP/GAPDH protein ratio (bottom; average of n = 2). sgROSA served as negative control and etoposide apoptosis inducer as positive control. D, Re-analysis of 7-AAD cell cycle assay staining using exact same gating parameters for sub-G1 cellular fraction indicative of apoptosis. E, Transwell cell migration assay. Fluorescence photomicrographs show calcein-stained migrated cells of sgBDNF-AS, sgGMDS-AS1, and sgXLOC_030781 knocked-down 501mel-dCas9-KRAB cells vs. sgROSA negative control and quantification of average sum count cell numbers (n = 2).
- Open Access
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Results XLOC_030781 KD RNA-Seq
- 9 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening
Results XLOC_030781 KD RNA-Seq